LOS ANGELES - Immix Biopharma, Inc. (NASDAQ:IMMX) announced that its NEXICART-2 trial achieved a 95% complete response rate in relapsed/refractory AL Amyloidosis patients.
19 of 20 patients reached complete response. All four patients previously minimal residual disease-negative converted to complete response. All complete responses were reached within one year of follow-up post-dosing.
No relapses have been observed to date for patients who reached complete response. All subsequently enrolled patients with available minimal residual disease results tested negative at one month.
The positive data contributed to a 328% stock return over the past year, though the stock declined 11% over the past week. The company's market capitalization is $474 million.
The NEXICART-2 trial evaluates NXC-201, a BCMA-targeted CAR-T cell therapy, in 45 patients with a registrational Phase 2 design.
The company plans to present updated data in late September 2026, and one-year follow-up data by March 2027.
NXC-201 has received Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the FDA, as well as Orphan Drug Designation from the FDA and EMA.
AL Amyloidosis is a disease where the immune system produces toxic light chains that accumulate in organs. The number of U.S. patients with relapsed/refractory AL Amyloidosis is estimated at approximately 38,500 in 2026.
Immix plans to initiate a Phase 3 trial in newly diagnosed patients. Analysts maintain a bullish outlook with price targets ranging from $14.80 to $23.
